Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 1.00 |
| ▸ | MAOB | P27338 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.92 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.92 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.92 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.92 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.92 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.92 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4213515 | 0.96 | CYP1A2 (1.00) | MAOAMAOBCYP1A2CYP2E1CYP3A4 | |
| SCHEMBL4217912 | 0.90 | MAOB (0.81) | MAOAMAOBCYP1A2CYP2E1CYP3A4 | |
| SCHEMBL4219807 | 0.90 | MAOB (0.81) | MAOAMAOBCYP1A2CYP2E1CYP3A4 | |
| SCHEMBL4211801 | 0.88 | MAOA (0.78) | MAOAMAOBCYP1A2CYP2E1CYP3A4 | |
| SCHEMBL4214762 | 0.88 | MAOB (0.78) | MAOAMAOBCYP1A2CYP2E1CYP3A4 | |
| SCHEMBL4206449 | 0.87 | MAOB (0.77) | MAOAMAOBCYP1A2CYP2E1CYP3A4 | |
| SCHEMBL4203685 | 0.87 | MAOB (0.83) | MAOAMAOB | |
| SCHEMBL4208357 | 0.86 | MAOB (0.77) | MAOAMAOB | |
| SCHEMBL4217717 | 0.86 | MAOB (0.78) | MAOAMAOB | |
| SCHEMBL4209626 | 0.85 | MAOB (0.74) | MAOAMAOBCYP1A2CYP2E1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090005436-A1 | Substituted Aminoalkyl- and Amidoalkyl-Benzopyran Derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2009-01-01 | — | — | US | claimed |
| CN-101137638-A | Substituted aminoalkyl-and amidoalkyl-benzopyran derivatives | NEWRON PHARM SPA (IT) | 2008-03-05 | — | — | CN | claimed |
| EP-1863784-A1 | SUBSTITUTED AMINOALKYL- AND AMIDOALKYL-BENZOPYRAN DERIVATIVES | Newron Pharmaceuticals S.p.A. (IT) | 2007-12-12 | — | — | EP | claimed |
| WO-2006102958-A1 | SUBSTITUTED AMINOALKYL- AND AMIDOALKYL-BENZOPYRAN DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2006-10-05 | — | — | WO | claimed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20090005436-A1 | Substituted Aminoalkyl- and Amidoalkyl-Benzopyran Derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2009-01-01 | — | — | US | disclosed |
| CN-101137638-A | Substituted aminoalkyl-and amidoalkyl-benzopyran derivatives | NEWRON PHARM SPA (IT) | 2008-03-05 | — | — | CN | disclosed |
| EP-1863784-A1 | SUBSTITUTED AMINOALKYL- AND AMIDOALKYL-BENZOPYRAN DERIVATIVES | Newron Pharmaceuticals S.p.A. (IT) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006102958-A1 | SUBSTITUTED AMINOALKYL- AND AMIDOALKYL-BENZOPYRAN DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005436-A1 | Substituted Aminoalkyl- and Amidoalkyl-Benzopyran Derivatives | MAOB, MAOA, AOC3 | MAOA 2/4885MAOB 1/4885CYP1A2 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.